Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17713565 | 0.98 | HRH1 (0.51) | HRH1PDE10ACYSLTR2CYSLTR1CXCR4 | |
| SCHEMBL19386131 | 0.94 | PDE10A (0.47) | HRH1PDE10ACYSLTR2CYSLTR1CXCR4 | |
| SCHEMBL2334595 | 0.88 | CYSLTR2 (0.52) | PDE10ACYSLTR2CYSLTR1NCF1NOS2 | |
| SCHEMBL30285321 | 0.86 | PDE10A (0.50) | HRH1PDE10ACYSLTR2CYSLTR1NCF1 | |
| SCHEMBL2305245 | 0.86 | PDE10A (0.50) | HRH1PDE10ACYSLTR2CYSLTR1NCF1 | |
| SCHEMBL6798820 | 0.86 | CYSLTR2 (0.53) | PDE10ACYSLTR2CYSLTR1NCF1NOS2 | |
| Iodide SCHEMBL28674252 | 0.85 | PDE10A (0.49) | HRH1PDE10ACYSLTR2CYSLTR1NCF1 | |
| Hydrochloric Acid SCHEMBL14352232 | 0.85 | PDE10A (0.49) | HRH1PDE10ACYSLTR2CYSLTR1MAPT | |
| SCHEMBL2913941 | 0.82 | PDE10A (0.61) | PDE10ACYSLTR2CYSLTR1NCF1NOS2 | |
| SCHEMBL8503996 | 0.81 | CYSLTR1 (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | claimed |
| CN-113121512-B | Preparation method of quinazolinyl butene amide compound | 江苏晶立信医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113121512-A | Preparation method of quinazolinyl butene amide compound | 江苏晶立信医药科技有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-20060148730-A1 | Using macrolide and ketolide compound | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-07-06 | — | — | US | disclosed |
| EP-1618119-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005007143-A2 | USE OF MAKROLIDES AND KETOLIDES FOR THE TREATMENT OF TUBERCULOSIS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014706-A1 | Method of treating tuberculosis | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2005-01-20 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| US-6100404-A | Erythromycin compounds | HOECHST MARION ROUSSEL (FR) | 2000-08-08 | — | — | US | disclosed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | disclosed |
| US-5635485-A | Erythromycin compounds | ROUSSEL UCLAF (FR) | 1997-06-03 | — | — | US | disclosed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | HRH1 3517/4885PDE10A 1118/4885CYSLTR2 2900/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | HRH1 2489/4885PDE10A 1947/4885CYSLTR2 1144/4885 |
| US-20060148730-A1 | Using macrolide and ketolide compound | MLYCD, TREH, TKT | HRH1 4030/4885PDE10A 2625/4885CYSLTR2 1617/4885 |
| US-20050014706-A1 | Method of treating tuberculosis | TREH, TKT, DCXR | HRH1 3801/4885PDE10A 1930/4885CYSLTR2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.